Current Oncology,
Год журнала:
2024,
Номер
32(1), С. 16 - 16
Опубликована: Дек. 28, 2024
Glioblastoma
(GBM)
is
a
primary
central
nervous
system
malignancy
with
median
survival
of
15–20
months.
The
presence
both
intra-
and
intertumoral
heterogeneity
limits
understanding
biological
mechanisms
leading
to
tumor
resistance,
including
immune
escape.
An
attractive
field
research
examine
treatment
resistance
are
signatures
composed
cluster
differentiation
(CD)
markers
cytokines.
CD
surface
expressed
on
various
cells
throughout
the
body,
often
associated
cells.
Cytokines
effector
molecules
system.
Together,
cytokines
can
serve
as
useful
biomarkers
reflect
status
in
patients
GBM.
However,
there
gaps
intricate
interactions
between
GBM
peripheral
how
these
change
standard
immune-modulating
treatments.
key
true
nature
through
multi-omic
analysis
progression
response.
This
review
aims
identify
potential
non-invasive
blood-based
that
contribute
an
signature
approaches,
better
involvement
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(20), С. 11225 - 11225
Опубликована: Окт. 18, 2024
Treatment
of
glioblastoma
is
ineffective.
Myx-M011L-KO/EGFP,
a
myxoma
virus
actively
inducing
apoptosis
in
BTICs
linked
to
recurrence,
offers
innovative
treatment.
We
loaded
this
construct
into
adipose-derived
stem
cells
(ADSCs)
mitigate
antiviral
host
responses
and
enable
systemic
delivery.
The
apoptotic
cytotoxic
effects
the
were
studied
using
murine
human
cell
lines.
Before
implementing
delivery,
we
delivered
locally
ADSC
verify
elimination
orthotopic
glioma
lesions.
vMyx-M011L-KO/EGFP
was
line,
preventing
effective
multiplication.
In
three
lines,
viral
replication
did
occur,
coupled
with
killing.
knock-out
induced
death
these
cultures.
ADSCs
infected
ex
vivo
shown
be
sufficiently
migratory
assure
transfer
therapeutic
cargo
Virus-loaded
applied
artificial
blood-brain
barrier
(BBB)
yielded
infection
grown
distally
wells.
Two
rounds
local
administration
platform
starting
6
days
post
tumor
implantation
slowed
down
growth
lesions
improved
survival
(total
recovery
<
20%).
show
promise
as
tool
Molecular Oncology,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 13, 2024
The
immunosuppressive
nature
of
the
tumor
microenvironment
poses
a
significant
challenge
to
effective
immunotherapies
against
glioblastoma
(GB).
Boosting
immune
response
is
critical
for
successful
therapy.
Here,
we
adopted
cancer
gene
therapy
approach
induce
T‐cell‐mediated
killing
through
increased
activation
system.
Patient‐based
three‐dimensional
(3D)
GB
models
were
infected
with
replication‐deficient
adenovirus
(AdV)
armed
class
II
major
histocompatibility
complex
(MHC‐II)
transactivator
(
CIITA
)
(Ad‐CIITA).
Successful
induction
surface
MHC‐II
was
achieved
in
cell
lines
and
primary
human
organoids.
Infection
an
AdV
carrying
mutant
form
single
amino
acid
substitution
resulted
cytoplasmic
accumulation
without
subsequent
expression.
Co‐culture
cells
either
peripheral
blood
mononuclear
(PBMCs)
or
isolated
T‐cells
led
dramatic
breakdown
Intriguingly,
both
wild‐type
Ad‐CIITA,
but
not
unarmed
AdV,
triggered
immune‐mediated
death
co‐culture
system,
suggesting
at
least
partially
MHC‐II‐independent
process.
We
further
show
that
observed
requires
presence
CD8
+
CD4
direct
contact
between
cells.
did
not,
however,
detect
evidence
canonical
pathways.
Although
precise
mechanism
remains
be
determined,
these
findings
highlight
potential
AdV‐mediated
delivery
enhance
immunity
GB.
Current Oncology,
Год журнала:
2024,
Номер
32(1), С. 16 - 16
Опубликована: Дек. 28, 2024
Glioblastoma
(GBM)
is
a
primary
central
nervous
system
malignancy
with
median
survival
of
15–20
months.
The
presence
both
intra-
and
intertumoral
heterogeneity
limits
understanding
biological
mechanisms
leading
to
tumor
resistance,
including
immune
escape.
An
attractive
field
research
examine
treatment
resistance
are
signatures
composed
cluster
differentiation
(CD)
markers
cytokines.
CD
surface
expressed
on
various
cells
throughout
the
body,
often
associated
cells.
Cytokines
effector
molecules
system.
Together,
cytokines
can
serve
as
useful
biomarkers
reflect
status
in
patients
GBM.
However,
there
gaps
intricate
interactions
between
GBM
peripheral
how
these
change
standard
immune-modulating
treatments.
key
true
nature
through
multi-omic
analysis
progression
response.
This
review
aims
identify
potential
non-invasive
blood-based
that
contribute
an
signature
approaches,
better
involvement
